Koopmans Anna E, Ober Kimberley, Dubbink Hendrikus J, Paridaens Dion, Naus Nicole C, Belunek Stephan, Krist Bart, Post Edward, Zwarthoff Ellen C, de Klein Annelies, Verdijk Robert M
Department of Ophthalmology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands Department of Clinical Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Invest Ophthalmol Vis Sci. 2014 Aug 26;55(9):6024-30. doi: 10.1167/iovs.14-14901.
Hot-spot mutations in the promoter region of telomerase reverse transcriptase (TERT promoter mutations) occur frequently in cutaneous and conjunctival melanoma and are exceedingly rare in uveal melanoma. No information is available on the presence of these mutations in the conjunctival melanocytic precursor lesion primary acquired melanosis (PAM). We tested a cohort of uveal and conjunctival melanomas as well as conjunctival benign and premalignant melanocytic lesions for TERT promoter mutations in order to elucidate the role of these mutations in tumor progression.
TERT promoter mutation analysis on fresh tumor DNA and DNA from formalin-fixed, paraffin-embedded specimens was performed by SNaPshot analysis in 102 uveal melanomas, 39 conjunctival melanomas, 26 PAM with atypia, 14 PAM without atypia, and 56 conjunctival nevi.
Mutations of the TERT promoter were not identified in conjunctival nevi or PAM without atypia, but were detected in 2/25 (8%) of PAM with atypia and 16/39 (41%) of conjunctival melanomas. A single TERT promoter mutation was detected in 102 uveal melanomas (1%).
We present the second documented case of TERT promoter mutation in uveal melanoma. In comparison with other types of melanoma, TERT promoter mutations occur at extremely low frequency in uveal melanoma. TERT promoter mutations are frequent in conjunctival melanoma and occur at lower frequency in PAM with atypia but were not detected in benign conjunctival melanocytic lesions. These findings favor a pathogenetic tumor progression role for TERT promoter mutations in conjunctival melanocytic lesions.
端粒酶逆转录酶启动子区域的热点突变(TERT启动子突变)在皮肤和结膜黑色素瘤中频繁出现,而在葡萄膜黑色素瘤中极为罕见。目前尚无关于结膜黑素细胞前驱病变原发性获得性黑素沉着症(PAM)中这些突变存在情况的信息。我们检测了一组葡萄膜和结膜黑色素瘤以及结膜良性和癌前黑素细胞病变中的TERT启动子突变,以阐明这些突变在肿瘤进展中的作用。
通过SNaPshot分析对102例葡萄膜黑色素瘤、39例结膜黑色素瘤、26例非典型性PAM、14例无非典型性PAM以及56例结膜痣的新鲜肿瘤DNA和福尔马林固定、石蜡包埋标本的DNA进行TERT启动子突变分析。
在结膜痣或无非典型性的PAM中未发现TERT启动子突变,但在2/25(8%)的非典型性PAM和16/39(41%)的结膜黑色素瘤中检测到突变。在102例葡萄膜黑色素瘤中检测到1例TERT启动子突变(1%)。
我们报告了葡萄膜黑色素瘤中第二例有记录的TERT启动子突变病例。与其他类型的黑色素瘤相比,TERT启动子突变在葡萄膜黑色素瘤中出现的频率极低。TERT启动子突变在结膜黑色素瘤中很常见,在非典型性PAM中出现频率较低,但在结膜良性黑素细胞病变中未检测到。这些发现支持TERT启动子突变在结膜黑素细胞病变的肿瘤发生进展中起作用。